Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lawrence Fong

Showing results (91-100 of 198) with videos related to

Pageof 20
Sort By:
Cancer Research|January 17, 2009
Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSFLawrence Fong, Serena S Kwek, Shaun O'Brien, et al.
Oncology Reports|October 6, 2011
A phase II study of insulin-like growth factor receptor inhibition with nordihydroguaiaretic acid in men with non-metastatic hormone-sensitive prostate cancerTerence W Friedlander, Vivian K Weinberg, Yong Huang, et al.
Immunity|December 13, 2023
TCR signaling promotes formation of an STS1-Cbl-b complex with pH-sensitive phosphatase activity that suppresses T cell function in acidic environmentsYuan-Li Tsai, Marcel Arias-Badia, Theresa A Kadlecek, et al.
Journal of the National Cancer Institute|August 12, 2023
The Cancer Moonshot Immuno-Oncology Translational Network at 5: accelerating cancer immunotherapiesAnanth Annapragada, Andrew G Sikora, Himangi Marathe, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 19, 2010
An autoimmune response to odorant binding protein 1a is associated with dry eye in the Aire-deficient mouseJason J DeVoss, Norbert P LeClair, Yafei Hou, et al.
Biorxiv : the Preprint Server for Biology|May 10, 2023
Tumor cell heterogeneity drives spatial organization of the intratumoral immune response in squamous cell skin carcinomaMiho Tanaka, Lotus Lum, Kenneth Hu, et al.
Cancer Immunology Research|April 8, 2024
PVRL2 Suppresses Antitumor Immunity through PVRIG- and TIGIT-independent PathwaysJiuling Yang, Li Wang, James R Byrnes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 26, 2010
Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancerKi Y Chung, Ira Gore, Lawrence Fong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2010
Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapyCharles J Ryan, Matthew R Smith, Lawrence Fong, et al.
Frontiers in Oncology|August 28, 2020
Phase II Study of Ipilimumab in Men With Metastatic Prostate Cancer With an Incomplete Response to Androgen Deprivation TherapyJulie N Graff, Mark N Stein, Rishi Surana, et al.
Pageof 20

Showing results (91-100 of 198) with videos related to

Sort By:
Pageof 20
Cancer Research|January 17, 2009
Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSFLawrence Fong, Serena S Kwek, Shaun O'Brien, et al.
Oncology Reports|October 6, 2011
A phase II study of insulin-like growth factor receptor inhibition with nordihydroguaiaretic acid in men with non-metastatic hormone-sensitive prostate cancerTerence W Friedlander, Vivian K Weinberg, Yong Huang, et al.
Immunity|December 13, 2023
TCR signaling promotes formation of an STS1-Cbl-b complex with pH-sensitive phosphatase activity that suppresses T cell function in acidic environmentsYuan-Li Tsai, Marcel Arias-Badia, Theresa A Kadlecek, et al.
Journal of the National Cancer Institute|August 12, 2023
The Cancer Moonshot Immuno-Oncology Translational Network at 5: accelerating cancer immunotherapiesAnanth Annapragada, Andrew G Sikora, Himangi Marathe, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 19, 2010
An autoimmune response to odorant binding protein 1a is associated with dry eye in the Aire-deficient mouseJason J DeVoss, Norbert P LeClair, Yafei Hou, et al.
Biorxiv : the Preprint Server for Biology|May 10, 2023
Tumor cell heterogeneity drives spatial organization of the intratumoral immune response in squamous cell skin carcinomaMiho Tanaka, Lotus Lum, Kenneth Hu, et al.
Cancer Immunology Research|April 8, 2024
PVRL2 Suppresses Antitumor Immunity through PVRIG- and TIGIT-independent PathwaysJiuling Yang, Li Wang, James R Byrnes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 26, 2010
Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancerKi Y Chung, Ira Gore, Lawrence Fong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2010
Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapyCharles J Ryan, Matthew R Smith, Lawrence Fong, et al.
Frontiers in Oncology|August 28, 2020
Phase II Study of Ipilimumab in Men With Metastatic Prostate Cancer With an Incomplete Response to Androgen Deprivation TherapyJulie N Graff, Mark N Stein, Rishi Surana, et al.
Pageof 20